



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspro.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/540,024	03/31/2000	Arthur O. Tzianabos	B0801/7169	1627
7590 11/24/2004			EXAMINER	
Helen C Lockhart			LIU, SAMUEL W	
Wolf Greenfield	d & Sacks PC			
600 Atlantic Avenue		ART UNIT	PAPER NUMBER	
Boston, MA 02210			1653	
			DATE MAILED: 11/24/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/540,024	TZIANABOS ET AL.				
, , , , , , , , , , , , , , , , , , ,	Examiner	Art Unit				
	Samuel W Liu	1653				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address				
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR RE	PLY [check either a) or b)]					
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. IE FINAL REJECTION. See MPEP				
fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 C	f extension and the corresponding amount he shortened statutory period for reply one the later than three months after the mail	unt of the fee. The appropriate extension				
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR	Brief must be filed within the pe	riod set forth in f the appeal				
2. The proposed amendment(s) will not be entered be	cause:					
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in issues for appeal, and/or		ially reducing or simplifying the				
(d) they present additional claims without canceling	ng a corresponding number of fir	nally rejected claims.				
NOTE:		*				
3. Applicant's reply has overcome the following rejecti	on(s):	*				
 Newly proposed or amended claim(s) would I canceling the non-allowable claim(s). 	pe allowable if submitted in a se	parate, timely filed amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See	reconsideration has been consideration Sheet.	dered but does NOT place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	suse it is not directed SOLELY to	sissues which were newly				
raised by the Examiner in the final rejection. 7. For purposes of Appeal, the proposed amendment(explanation of how the new or amended claims we	s) a) will not be entered or b) [uld be rejected is provided below	☑ will be entered and an − w o r appende d.				
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: none.						
Claim(s) objected to: 7-10,13,150,151 and 157.		,				
Claim(s) rejected: 1, 6, 11-12, 14-19, 149, 152-156 an	<u>d 158-163</u> .					
Claim(s) withdrawn from consideration: none.						
The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement	•					
0. Other:	, , , =================================					
		į.				
A						

Continuation of 5. does NOT place the application in condition for allowance because: The claim rejection under 35 USC 102, mailed 20 July 2004, stands for the same reasons set forth in the Office action. Applicants argue that the Ferrari's composition does not composed entirely of identical repeating units. The Applicants' argument is unpersausive because the Ferrari's composition does entirely comprise five identical repeating units (peptides) (see the Office action , pages 3-6), which meets the limitations set forth in the instant claims rejected.

The claim rejection under 35 USC 112, the second paragraph in the previous Office action mailed 20 July 2004 stands for the same reasons set forth in the Office action. Applicant's reply to the Office action argues that "non-native polypeptide" (claim 15) is not unclear as the specification defines "non-native polymer". The applicatants' argument is unpersuasive because the specification does not expressly defines the non-native polypeptide (note that definition of "non-native polymer" cannot substitute for definition of "non-native polypeptide" because polymer broadly encomapsses biopolymer, e.g., lipid, nucleic acid and polypeitde/protien and naturally-occuring and chemically synthesized polymer).

Applicants also argue that claim 154 recitation "adjacent amino acids" refers to protein/polypeptide primary structure (i.e., amino acid sequence) not higher structure of the protein/polypeptide, e.g., ternary structure; and thus, the recitation is clear. The applicants' argument is found to be unpersuasive because nowhere sets forth in the specification that the polypeptide structure in the claimed polymer molecule only be limited to the primary structure. Thus, the term "adjacent" in said recitation ambiguously encompasses the higher polypeptide/protein structures, which renders the claim indefinite.

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

Low Cahene Carborker